ClinicalTrials.gg

Program

nefextinib

Also written as “MAX-40279-01”, “MAX-40279” and “MAX-40279-01: 50mg/70mg”.

Its studies are mostly in Leukemia, Myeloid, Acute · Stomach Neoplasms · Colorectal Neoplasms, led by Maxinovel Pty..

Furthest: phase 2, since Sep 18, 20219 company-led studies, 1 open or runningNext primary completion: Sep 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Maxinovel Pty.91 open or runningphase 2since Sep 18, 2021Jan 8, 2018Sep 1, 2027phase 2 · NCT07743112

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 8, 2018First study: phase 1 study in Leukemia, Myeloid, AcuteFirst studyNCT03412292 · 30 enrolled · Australia
  2. Nov 28, 2019Phase 1 study in Solid TumorNCT04183764 · 30 enrolled · China
  3. Dec 3, 2019Phase 1 study in AMLNCT04187495 · 30 enrolled · China
  4. Sep 18, 2021Phase 2 study in LeukemiaNCT05061147 · 100 enrolled · China
  5. Nov 10, 2021Phase 2 study in Colorectal NeoplasmsNCT05130021 · 130 enrolled · China
  6. Apr 18, 2022Phase 2 study in Advanced / Metastatic Solid TumorsNCT05425602 · 108 enrolled
  7. Apr 26, 2022Phase 1 study in Solid TumorNCT05369286 · 28 enrolled · China
  8. May 19, 2022Phase 2 study in Stomach NeoplasmsNCT05395780 · 30 enrolled · China
  9. Jul 29, 2026Phase 2 study in Leukemia, Myeloid, AcuteNCT07743112 · 43 planned · China

Ahead

  1. Sep 1, 2027Primary completion: phase 2 study in Leukemia, Myeloid, AcuteNCT07743112

TargetBeta

FLT3 →read by rule
“An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), ”NCIt, by rule

Other programs on FLT3

ProgramCompanyFurthest phaseStudies
jaktinibruleSuzhou Zelgen Biopharmaceuticalsphase 331
quizartinibruleDaiichi Sankyophase 322
gilteritinibruleAstellas Pharmaphase 320
pacritinibruleSwedish Orphan Biovitrumphase 318
AXL/FLT3/VEGFR2 Inhibitor KC1036rulebeijing-konruns-pharmaceutical-co-ltdphase 37
flonoltinibruleChengdu Zenitar Biomedical Technologyphase 37
FLT3 Inhibitor XY0206ruleshijiazhuang-yiling-pharmaceutical-co-ltdphase 35
Anti-FLT3/CD3 Bispecific Antibody CLN-049rulecullinan-therapeutics-incphase 22
flonoltinib maleateruleChengdu Zenitar Biomedical Technologyphase 22
HPB-092rulehangzhou-polymed-biopharmaceuticals-incphase 11

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07743112Leukemia, Myeloid, Acute · China2RecruitingSep 1, 202743
NCT05395780Stomach Neoplasms · China2UNKNOWNDec 202230
NCT05369286Solid Tumor · China1UNKNOWNMay 31, 202328
NCT05425602Advanced / Metastatic Solid Tumors2UNKNOWNDec 30, 2023108
NCT05130021Colorectal Neoplasms · China2UNKNOWNMay 30, 2022130
NCT05061147Leukemia · China2UNKNOWNApr 30, 2022100
NCT04187495AML · China1UNKNOWNDec 1, 202230
NCT04183764Solid Tumor · China1UNKNOWNNov 1, 202230
NCT03412292Leukemia, Myeloid, Acute · Australia1UNKNOWNNov 1, 202230

How it is read

Names in the registry

  • “MAX-40279-01”, 4 entries
  • “MAX-40279”, 3 entries
  • “MAX-40279-01: 50mg/70mg”, 1 entry
  • “"MAX-40279-01" and "Toripalimab"”, 1 entry

Codes read as this program: MAX4027901.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.